West Pharmaceutical Services, Inc. Q3 2025 Earnings Recap

WST Q3 2025 October 23, 2025

West's Q3 2025 results exceeded expectations with revenues up 5% to $805 million and adjusted EPS rising 6% to $1.96, prompting an increase in FY 2025 guidance.

Earnings Per Share Beat

$1.96 vs $1.68 est.

+16.7% surprise

Revenue Beat

804300000 vs 785707675 est.

+2.4% surprise

Key Takeaways

Proprietary Products segment delivered $648 million in revenues, a 5.1% organic increase, driven by strong HVP components related to GLP-1 sales.
Adjusted operating margins improved to 21.1%, underscoring operational efficiency.
The company has 375 ongoing Annex 1 upgrade projects, boosting growth expectations from 150 to 200 basis points in 2025.
Contract Manufacturing segment revenues grew 4.9% organically, benefiting from consolidation efforts in Arizona.
Leadership transitions, including a new CFO and CTO, are strategically positioned to enhance innovation and operational growth.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit WST on AllInvestView.

Previous Q2 2025